These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38801240)

  • 1. Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS-CoV-2 Main Protease with Antiviral Activity.
    Harrison K; Carlos PW; Ullrich S; Aggarwal A; Johansen-Leete J; Sasi VM; Barter I; Maxwell JWC; Bedding MJ; Larance M; Turville S; Norman A; Jackson CJ; Nitsche C; Payne RJ
    Chemistry; 2024 Aug; 30(44):e202401606. PubMed ID: 38801240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.
    Citarella A; Dimasi A; Moi D; Passarella D; Scala A; Piperno A; Micale N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
    Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
    J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
    Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cyclic peptide inhibitor of the SARS-CoV-2 main protease.
    Kreutzer AG; Krumberger M; Diessner EM; Parrocha CMT; Morris MA; Guaglianone G; Butts CT; Nowick JS
    Eur J Med Chem; 2021 Oct; 221():113530. PubMed ID: 34023738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review.
    Xiao YQ; Long J; Zhang SS; Zhu YY; Gu SX
    Bioorg Chem; 2024 Jun; 147():107380. PubMed ID: 38636432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.
    Freire MCLC; Noske GD; Bitencourt NV; Sanches PRS; Santos-Filho NA; Gawriljuk VO; de Souza EP; Nogueira VHR; de Godoy MO; Nakamura AM; Fernandes RS; Godoy AS; Juliano MA; Peres BM; Barbosa CG; Moraes CB; Freitas-Junior LHG; Cilli EM; Guido RVC; Oliva G
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
    Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS
    Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.
    Jiang Y; Wu Y; Wang J; Ma Y; Yu H; Wang Z
    Curr Med Chem; 2024; 31(38):6204-6226. PubMed ID: 38529602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
    Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33503819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease.
    Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS
    Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
    Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
    Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Gao K; Wang R; Chen J; Tepe JJ; Huang F; Wei GW
    J Med Chem; 2021 Dec; 64(23):16922-16955. PubMed ID: 34798775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of highly potent SARS-CoV-2 M
    Chen W; Feng B; Han S; Wang P; Chen W; Zang Y; Li J; Hu Y
    Bioorg Med Chem Lett; 2022 Feb; 58():128526. PubMed ID: 34998903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 M
    Hu Q; Zhang Y; Chen P; Zhang Y; Zhu G; Liu W; Wang C; Zheng S; Shen N; Wang H; Huang P; Ge G
    Chin J Nat Med; 2024 Sep; 22(9):797-807. PubMed ID: 39326974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.